• In May 2026, Personalis, Inc. announced that CMS’s Molecular Diagnostic Services Program expanded Medicare coverage for its NeXT Personal minimal residual disease test to include monitoring neoadjuvant therapy response in Stage II–III triple-negative and HER2-positive breast cancer patients.
• This decision, supported by the PREDICT-DNA study showing the value of ultrasensitive ctDNA monitoring below 100 parts per million, broadens NeXT Personal’s clinical role in guiding treatment before surgery.
• Next, we’ll explore how this expanded Medicare coverage for neoadjuvant treatment monitoring could influence Personalis’ longer-term investment narrative.

Find 46 companies with promising cash flow potential yet trading below their fair value.

Personalis Investment Narrative Recap

To own Personalis, you need to believe NeXT Personal can become a widely used minimal residual disease test in high-value cancer settings, and that reimbursement will ultimately support a sustainable business despite current losses. The new Medicare expansion into neoadjuvant breast cancer slightly strengthens the near term reimbursement catalyst by broadening covered use, but it does not remove the major risk around high cash burn, ongoing operating losses, and potential future dilution.

The most relevant recent announcement is the May 13 MolDX decision to cover NeXT Personal for immunotherapy response monitoring in late stage solid tumors. Together with the new neoadjuvant breast cancer coverage, Personalis now has multiple Medicare backed use cases that align directly with its key catalyst of accelerating NeXT Personal adoption, while still leaving execution, competition, and biopharma R&D exposure as important open questions.

Yet even with these coverage wins, investors should be aware that Personalis still faces meaningful cash burn and funding risk over the coming years...

Personalis' narrative projects $162.9 million revenue and $25.4 million earnings by 2029. This requires 36.2% yearly revenue growth and a $121 million earnings increase from -$95.6 million today.

Uncover how Personalis' forecasts yield a $10.86 fair value, a 5% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue reaching about US$163.2 million by 2028, yet they also flagged intense MRD competition as a key threat; this new Medicare decision could eventually shift those views, but it also shows how differently you and other investors might weigh upside against execution and rivalry risks.

Explore 2 other fair value estimates on Personalis - why the stock might be worth just $10.86!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Personalis research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Personalis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Personalis' overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.